GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Pretax Margin %

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Pretax Margin % : -2,665.22% (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. IntelliPharmaCeutics International's Pre-Tax Income for the three months ended in Aug. 2023 was $-1.84 Mil. IntelliPharmaCeutics International's Revenue for the three months ended in Aug. 2023 was $0.07 Mil. Therefore, IntelliPharmaCeutics International's pretax margin for the quarter that ended in Aug. 2023 was -2,665.22%.

The historical rank and industry rank for IntelliPharmaCeutics International's Pretax Margin % or its related term are showing as below:

IPCIF' s Pretax Margin % Range Over the Past 10 Years
Min: -4365.17   Med: -239.5   Max: -43.97
Current: -343.98


IPCIF's Pretax Margin % is ranked worse than
59.4% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs IPCIF: -343.98

IntelliPharmaCeutics International Pretax Margin % Historical Data

The historical data trend for IntelliPharmaCeutics International's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Pretax Margin % Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -802.51 -232.40 -239.51 - -4,374.24

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,557.89 -2,896.67 -109.20 -11.25 -2,665.22

Competitive Comparison of IntelliPharmaCeutics International's Pretax Margin %

For the Biotechnology subindustry, IntelliPharmaCeutics International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Pretax Margin % falls into.



IntelliPharmaCeutics International Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

IntelliPharmaCeutics International's Pretax Margin for the fiscal year that ended in Nov. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Nov. 2022 )/Revenue (A: Nov. 2022 )
=-2.887/0.066
=-4,374.24 %

IntelliPharmaCeutics International's Pretax Margin for the quarter that ended in Aug. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Aug. 2023 )/Revenue (Q: Aug. 2023 )
=-1.839/0.069
=-2,665.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


IntelliPharmaCeutics International Pretax Margin % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.